Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib [Yahoo! Finance]
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results